CoChat
Sign Up
Cited by 51Viral-associated cancers and disordersCytomegalovirus and herpesvirus researchLymphoma Diagnosis and Treatment

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Open access
Ramaswami, Ramya, Lurain, Kathryn, Peer, Cody J., Serquiña, Anna, Wang, Victoria, Widell, Anaida, Goncalves, Priscila, Steinberg, Seth M. +7 more·2020·Blood
DOI 10.1182/blood.2019004602PMC PMC7316216
Open this paper in CoChat — free account

Abstract

Kaposi sarcoma (KS) herpesvirus (KSHV), also known as human herpesvirus-8, is the causative agent for KS and a plasmablastic form of multicentric Castleman disease (MCD; KSHV-MCD). 1 KSHV-MCD is a relapsing and remitting B-cell lymphoproliferative disorder that occurs primarily in people living with HIV. 2,3Patients present with anemia, thrombocytopenia, and inflammatory symptoms associated with elevated cytokines including interleukin-6 (IL-6) and IL-10, elevated levels of C-reactive protein (CRP), and elevated KSHV viral loads (KSHV-VLs).5][6] Treatment options include rituximab (a humanized monoclonal antibody against CD20), rituximab with liposomal doxorubicin or etoposide, or virus-activated cytotoxic therapy with high-dose zidovudine (AZT) and valganciclovir (VGC). 7-13However, some patients do not respond to rituximab, and, when used alone, it is associated with worsening or development of KS in 35% to 67%. 8,9

Integrity signals

Registry

Crossref · 10.1182/blood.2019004602

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tocilizumab has minimal and short-lived effect in patients with HHV-8-associated multicentric Castleman's disease, most likely because of viral interleukin-6 signaling independent of the neutralized interleukin-6 receptor.

    “A recent study showed that the effect of tocilizumab in patients with HHV-8–associated multicentric Castleman’s disease was minimal and short-lived, most likely because of viral interleukin-6 signaling that was independent of the neutralized interleukin-6 receptor.70”

    From Cytokine storm (2020) · cites this paper as [70]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Ramaswami, R., Lurain, K., Peer, C. J., Serquiña, A., Wang, V., Widell, A., Goncalves, P., Steinberg, S. M., Marshall, V., George, J., Figg, W. D., Whitby, D., Ziegelbauer, J., Uldrick, T. S., & Yarchoan, R.
Affiliations
  • HIV & AIDS Malignancy Branch,
  • Clinical Pharmacology Program, and
  • National Institutes of Health (US)
  • Frederick National Laboratory for Cancer Research (US)
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2020-06-18
Volume
135
Issue
25
Pages
2316-2319
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood.2019004602
PMC
PMC7316216
OpenAlex
W3015640978
Cited by
51
References
20
Citations by year
2026: 6 · 2025: 5 · 2024: 9 · 2023: 6 · 2022: 9 · 2021: 12 · 2020: 4
FWCI
2.80
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (HHSN261200800001C)
  • National Cancer Institute (HHSN261200800001E), 75N91019D00024)
Topics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
tocilizumab, Kaposi's sarcoma-associated herpesvirus, interleukin-6, IL-10, rituximab resistance, B-cell lymphoproliferative disorders, cytokine inhibition
MeSH terms
Valganciclovir, Adult, Female, Castleman Disease, Herpesviridae Infections, Humans, Male, Middle Aged, Sarcoma, Kaposi, Zidovudine, HIV Infections, Interleukin-10, Treatment Outcome, Herpesvirus 8, Human, Anti-HIV Agents, Viral Load, Interleukin-1beta, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review